- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04438382
Infliximab en intraveneuze immunoglobulinetherapie bij de behandeling van patiënten met steroïde-refractaire pneumonitis
Immunosuppressie optimaliseren voor steroïde-refractaire anti-PD-1/PD-L1-pneumonitis
This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment. Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Intravenous immunoglobulin therapy may improve pneumonitis. It is not yet known whether giving infliximab and intravenous immunoglobulin therapy will work better in treating patients with pneumonitis.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To assess pneumonitis response to additional immunosuppression (infliximab or intravenous immunoglobulin therapy [IVIG]) in patients with steroid-refractory pneumonitis at 28-days.
SECONDARY OBJECTIVES:
I. To assess functional parameters of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG).
II. To assess radiologic parameters of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG).
III. To assess patient-reported outcomes of steroid-refractory pneumonitis at day 1, 14-days and 28-days after day 1 of receipt of additional immunosuppression (infliximab or IVIG).
IV. To assess death after additional immunosuppression. V. To assess the rate of infections in the 28-day period after additional immunosuppression.
EXPLORATORY OBJECTIVES:
I. To examine lung tissue, bronchoalveolar lavage (BAL) and serial blood samples in patients who develop steroid-refractory pneumonitis.
II. To examine associations between BAL phenotypes and pneumonitis response, functional and radiologic parameters of pneumonitis.
III. To evaluate associations between pneumonitis and autoantibodies, T-cell expansion, and baseline cytokines in the blood.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive infliximab intravenously (IV) on day 1 followed by prednisone taper IV or orally (PO) for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician.
ARM B: Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 28, 42 and 56 days.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Michigan
-
Battle Creek, Michigan, Verenigde Staten, 49017
- Bronson Battle Creek
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Spectrum Health at Butterworth Campus
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Mercy Health Saint Mary's
-
Kalamazoo, Michigan, Verenigde Staten, 49007
- West Michigan Cancer Center
-
Muskegon, Michigan, Verenigde Staten, 49444
- Mercy Health Mercy Campus
-
Niles, Michigan, Verenigde Staten, 49120
- Lakeland Hospital Niles
-
Norton Shores, Michigan, Verenigde Staten, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Verenigde Staten, 49677
- Spectrum Health Reed City Hospital
-
Saint Joseph, Michigan, Verenigde Staten, 49085
- Lakeland Medical Center Saint Joseph
-
Saint Joseph, Michigan, Verenigde Staten, 49085
- Marie Yeager Cancer Center
-
Traverse City, Michigan, Verenigde Staten, 49684
- Munson Medical Center
-
Wyoming, Michigan, Verenigde Staten, 49519
- Metro Health Hospital
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19111
- Fox Chase Cancer Center
-
-
Virginia
-
Richmond, Virginia, Verenigde Staten, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Verenigde Staten, 23298
- Virginia Commonwealth University/Massey Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Patients must be English-speaking and be able to provide informed consent
-
Patient must be willing and able to undergo arterial blood gas assessment as per the treating investigator. Patient must not have contraindication for arterial blood gas assessment
-
Women must not be pregnant or breast-feeding due to the potential risk to the fetus of infliximab or IVIG. All females of childbearing potential must have a blood test or urine test within 14 days prior to randomization to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
-
Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method(s) of contraception or to abstain from sexual intercourse for a minimum of 56 days (the duration of their participation in the study)
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
-
Patient may have received any number of lines of prior systemic therapy
-
Patient may have any solid tumor or hematologic malignancy is eligible
-
Patient must have received treatment with an anti-PD-1/PD-L1 agent either alone or in combination with another anti-cancer agent, as their most recent therapy prior to development of pneumonitis
-
Patient must have steroid-refractory pneumonitis defined as:
- Grade 2 pneumonitis that has not clinically improved by a Common Terminology Criteria for Adverse Events (CTCAE) grade in greater than 72 hours or maximum of 14 days or
- Grade 3 or higher pneumonitis that has not clinically improved by a CTCAE grade in greater than 48 hours or maximum of 14 days with high dose corticosteroids (methylprednisolone or prednisone 1-4 mg/kg/equivalent) as their most recent treatment for pneumonitis, as determined by the treating investigator
-
Patient may have received anti-PD-1/PD-L1 therapy as standard-of-care or part of a clinical trial
-
Patient must have had pathogen-negative infectious diagnostic evaluation within 14 days prior to randomization, and at a minimum these should include: blood culture, urine culture, sputum culture, and viral panel: rapid flu, respiratory syncytial virus (RSV), herpes simplex virus (HSV). Empiric antibiotics for culture negative infections are not an exclusion for study entry
-
Patient must have had a pathogen-negative bronchoscopic assessment of BAL fluid within 14 days prior to randomization. A minimum assessment for pathogens on BAL must include: gram stain, fungal panel, viral panel
-
Patient must have a negative tuberculosis assessment (TB spot test, quantiferon gold or tuberculin skin test) within 14 days prior to randomization
-
Patient must have chest computed tomography (CT) scan without contrast performed =< 14 days before randomization. Patient must not have a contraindication for CT
Exclusion Criteria:
- Patient must not have clinical evidence of cardiac dysfunction (as determined by the treating investigator) as an alternative diagnosis to steroid-refractory pneumonitis
- Patient must not be receiving anti-PD-1/-PD-L1 agent in combination with any of the following anti-cancer agents: docetaxel, cyclophosphamide, gefitinib, erlotinib, osimertinib, crizotinib, bleomycin, afatinib
- Patient must not be receiving concurrent radiation therapy to the chest
- Patient must not be deemed to have radiation pneumonitis. Patients with a history of stable radiation pneumonitis not requiring corticosteroid therapy within the last 3 months prior to randomization will be allowed on study
- Patient must not have pre-existing interstitial lung disease or pneumonitis requiring corticosteroid therapy from any other cause, as determined by the treating investigator
- Patient must not have an absolute contraindication to IVIG or infliximab, including: clinical history of severe hypersensitivity reaction, selective IgA deficiency, active hepatitis B, active tuberculosis, active human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) where a study subject has a CD4 count of =< 200 at screening, or drug interaction
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A (infliximab)
Patients receive infliximab IV on day 1 followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician. |
Given IV
Andere namen:
Given IV or PO
Andere namen:
Given IV or PO
Andere namen:
|
|
Experimenteel: Arm B (intravenous immunoglobulin therapy)
Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity. |
Given IV or PO
Andere namen:
Given IV or PO
Andere namen:
Given IV
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pneumonitis Response Rate
Tijdsspanne: At day 28
|
Pneumonitis response will be defined as an improvement in partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) of >= 20% measured by PaO2 and recording of the FiO2 received by the patient at the time of the arterial blood gas assessment, on day 28 compared with day 1. |
At day 28
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of Patients With Radiologic Response for Steroid-refractory Pneumonitis
Tijdsspanne: At days 1, 14, and 28
|
Radiologic features of steroid-refractory pneumonitis will be assessed by percentage lung parenchyma involved, percentage of ground-glass opacity in lung parenchyma, and lung volume on computed tomography. The pneumonitis and lung volume will be graded "Definitely decreased", "Probably decreased", "No significant change", "Probably increased" and "Definitely increased". Response to study therapy will be defined by combining the categories "Definitely decreased" and "Probably decreased". |
At days 1, 14, and 28
|
|
Functional Parameters of Steroid-refractory Pneumonitis by Spirometry
Tijdsspanne: At days 1, 14, and 28
|
Functional features of pneumonitis will be assessed by spirometry (forced vital capacity, forced expiratory volume in one second). These quantitative measures will be reported descriptively (by median, mean, and range) by timepoints and treatment arms. |
At days 1, 14, and 28
|
|
Functional Parameters of Steroid-refractory Pneumonitis by Diffusion Capacity
Tijdsspanne: At days 1, 14, and 28
|
Functional features of pneumonitis will be assessed by diffusion capacity of the lung. These quantitative measures will be reported descriptively (by median, mean, and range) by timepoints and treatment arms. |
At days 1, 14, and 28
|
|
Functional Parameters of Steroid-refractory Pneumonitis by Oxygen Saturation
Tijdsspanne: At days 1, 14, and 28
|
Functional features of pneumonitis will be assessed by oxygen saturation on room air at rest, collected as part of the vital signs. These quantitative measures will be reported descriptively (by median, mean, and range) by timepoints and treatment arms. |
At days 1, 14, and 28
|
|
Number of Deaths Within 28 Days
Tijdsspanne: Up to 28 days
|
Death reported in the 28-day period will be tabulated by treatment arm, and classified as pneumonitis-related, immunosuppression related, disease-related or other. |
Up to 28 days
|
|
Incidence of Adverse Events
Tijdsspanne: Up to 28 days
|
Will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The number and severity of treatment-related adverse events from infections in any organ system by the CTCAE reported in the 28-day period after additional immunosuppression. |
Up to 28 days
|
|
Total Score of Functional Assessment of Cancer Therapy - Lung Version 4
Tijdsspanne: At days 1, 14, and 28
|
Patient-reported outcomes of steroid-refractory pneumonitis will be measured by questionnaires (Functional Assessment of Cancer Therapy - Lung version 4 [FACT-L]). FACT-L consists of 5 subscales and the total score is calculated by summing the scores of the 36 items. The score ranges between 0 and 136. The higher the score, the better the quality of life. |
At days 1, 14, and 28
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Distribution of Biomarkers in Patients Who Develop Steroid-refractory Pneumonitis
Tijdsspanne: Days 1, 14 and 28 after study treatment
|
Potential blood/serum biomarkers for pneumonitis will be assessed from serially collected blood/serum in accrued patients (on Days 1, 14 and 28 after study treatment) and controls, whose blood/serum will be obtained as part of a parallel tissue-collection protocol. |
Days 1, 14 and 28 after study treatment
|
|
To Evaluate Associations Between Pneumonitis and Autoantibodies, T Cell Expansion, and Baseline Cytokines in the Blood
Tijdsspanne: On days 1, 14, and 28 post-treatment
|
To evaluate associations between pneumonitis and autoantibodies, T cell expansion, and baseline cytokines in the blood. |
On days 1, 14, and 28 post-treatment
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Jarushka Naidoo, ECOG-ACRIN Cancer Research Group
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Hematologische ziekten
- Hemische en lymfatische ziekten
- Hematologische neoplasmata
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Polycyclische verbindingen
- Antilichamen, monoklonaal
- Antilichamen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Zwangerschap
- Zwangere
- Steroïden
- Verbindingen met gefuseerde ring
- Zwangerschap
- Zwangerschap
- Immunoglobuline -isotypes
- Immunoglobuline G
- Prednisolon
- Methylprednisolonacetaat
- Infliximab
- Prednison
- Immunoglobulinen
- Methylprednisolon
- Methylprednisolon-hemisuccinaat
- Immunoglobulinen, intraveneus
- gamma-globulinen
Andere studie-ID-nummers
- EAQ172
- EAQ172 (Andere identificatie: CTEP)
- NCI-2018-02825 (Register-ID: CTRP (Clinical Trial Reporting Program))
- UG1CA189828 (Subsidie/contract van de Amerikaanse NIH)
- EAQ172 (Andere identificatie: ECOG-ACRIN Cancer Research Group)
- EAQ172 (Andere identificatie: DCP)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .